Raymond James analyst Adam Tindle upgraded SYNNEX two notches to Strong Buy from Market Perform and established a $122 price target on shares saying key metrics are "poised to inflect." Tindle said shares have meaningfully underperformed and he sees several potential catalysts ahead that include a acceleration in TTM free cash flow as high inventory is sold, an acceleration in the Hyve business that should drive margins, and double-digit operating margins in FY18 as Concentrix grows into investments. The analyst also sees optionality from corporate tax reform and potential M&A.